Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Bagsværd, 5 February 2025 - Financial report for the period 1 January…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…